|
|
Tumors
of the Osseous Spine
Narayan Sundaresan, Stephano
Boriani, Allen Rothman, Robert Holtzman
Department
of Neurosurgery, Mount Sinai Medical Center, 1148 Fifth Avenue, NY
10128, New York, USA; Tel.: +1-212-876-7575; E-mail: Narayan.sundaresan@mssm.edu
[N.S.].
Ospedale Maggiore, Insitute Rizzoli, Bologna, Italy [S.B.].
Department of Neurosurgery, Mount Sinai Medical Center,
New York, NY [A.R.]. Department of Neurosurgery, Lenox Hill Hospital,
New York, NY, USA [R.H.].
Recent
advances in molecular biology with the development of novel
therapeutic agents, as well as fundamental understanding of the
mechanisms of bone metastases have greatly altered the therapeutic
options in patients with spine tumors.
Improvements in spine instrumentation as well as the development of
recombinant Bone Morphogenetic Protein for spine reconstruction and
fusion offers promising hope for curative strategies in selected
patients.
A clearer application of the fundamentals of surgical oncology applied
to spine tumors should result in a greater proportion of patients
undergoing surgically appropriate en bloc resections for spine
tumors.
Finally, the superiority of surgery over external irradiation in the
controlled clinical trial setting should greatly expand the pool of
patients requiring surgery.
In this review, we consider the recent advances in primary bone tumors
including chordoma, sarcomas, multiple myeloma, as well as metastatic
cancer to the spine.
Keywords:
bone sarcoma, chordoma, metastatic spine tumor, osteosarcoma,
spine tumors
Copyright
©
2004 Kluwer Academic Publishers.
All rights reserved
Source: http://ipsapp007.kluweronline.com/IPS/content/ext/x/J/5042/I/124/A/21/abstract.htm
|
